revanc report net loss per share cash balanc
inclus net proce recent equiti offer decemb notabl
compani announc collabor develop biosimilar allergan
botox addit monet botulinum toxin bt expertis view
give form downsid protect extent competit
environ intensifi beyond expect see steadi stream mileston
includ data long-term safeti studi glabellar line gl
given strength phase data gl would continu view
pipelin within product reiter overweight rate lower pt
owe higher oper expens estim multipl discount
detail collabor partner develop
manufactur commerci biosimilar allergan botox agreement
includ up-front payment along payment
relat certain clinic regulatori mileston payment relat
sales-bas mileston global commerci right product
would interpret agreement would argu whether
intend case agreement regard botox
biosimilar view form downsid protect extent
botox biosimilar emerg put anoth way way particip
wider chunk bt market context declin price environ whether
due brand bt product botox biosimilar therebi offset
potenti damag damag term lower net realiz price oppos
lower volum bottom line view creativ way
broaden particip neuromodul space minimum monet
compani bt expertis
latest color gl therapeut indic enrol sakura
long-term safeti studi gl set complet data expect
regard develop program cervic dystonia cd plan
initi phase program recal grant orphan drug statu
indic regard develop program plantar fasciiti pf
plan run second phase iia trial incorpor differ design
compar unsuccess previou phase ii studi
risk includ clinic regulatori setback
revanc focus next-gener neuromodul treatment
non-gaap ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
actual versu pjc consensu estim
consensu estim
compani report factset pjc estim
page
million except per share itemsactualspjc royalti revenu ep dilut exhibit
reflect sign ex-u partnership estim royalti ex-u sale assum european launch
consensu estim
report non-gaap oper expens non-gaap ep futur estim base histor may reflect pjc estim
compani report factset pjc estim
page
million except per glabellar line indic royalti revenu outstand ep dilut quarterli annual incom statement
million except ep
 glabellar line
 indic
ex-u royalti revenu
sale
sell gener administr
incom loss tax
expens total sale
sell gener administr
sell gener administr
proprietari piper jaffray februari
reflect sign ex-u partnership estim royalti ex-u sale assum european launch
paid interest exclud non-cash interest expens actual reflect ep beyond reflect non- may pjc estim
current disclosur inform compani found
page
million
chang work capit
acquisit tangibl asset
acquisit intang
stock option issuanc
reflect pjc estim compani becom avail
proprietari piper jaffray februari
page
million
goodwil intang asset
proprietari piper jaffray februari
page
